|
|
| | CCG-1423 Basic information |
| Product Name: | CCG-1423 | | Synonyms: | CCG-1423;N-(2-(4-Chloroanilino)-1-Methyl-2-oxoethoxy)-3,5-bis(trifluoroMethyl)benzaMide;N-(1-(4-chlorophenylaMino)-1-oxopropan-2-yloxy)-3,5-bis(trifluoroMethyl)benzaMide;N-({1-[(4-Chlorophenyl)Amino]-1-Oxo-2-Propanyl}Oxy)-3,5-Bis(Trifluoromethyl)Benzamide CCG-1423;N-[2-[(4-Chlorophenyl)amino]-1-methyl-2-oxoethoxy]-3,5-bis(trifluoromethyl)-benzamide;N-[1-(4-chloroanilino)-1-oxopropan-2-yl]oxy-3,5-bis(trifluoromethyl)benzamide;Rho/SRF Pathway Inhibitor, CCG-1423;CCG-1423 USP/EP/BP | | CAS: | 285986-88-1 | | MF: | C18H13ClF6N2O3 | | MW: | 454.75 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 285986-88-1.mol |  |
| | CCG-1423 Chemical Properties |
| storage temp. | Sealed in dry,Store in freezer, under -20°C | | solubility | DMSO: soluble5mg/mL, clear (warmed) | | form | White solid | | color | white to beige |
| WGK Germany | 3 | | HS Code | 2924.29.7790 |
| | CCG-1423 Usage And Synthesis |
| Uses | CCG-1423 is a specific RhoA pathway inhibitor, inhibiting SRF-mediated transcription which has been implicated in cancer and fibrosis. | | storage | +4°C |
| | CCG-1423 Preparation Products And Raw materials |
|